Sfoglia per AUTORE
FEA E
Collezione AO Cuneo

  

Items : 7

Patients with cancer and hospital admissions: disease trajectory and strategic choices. in BMJ supportive & palliative care / BMJ Support Palliat Care. 2023 Sep 13:spcare-2023-004574. doi: 10.1136/spcare-2023-004574.
2023
AO Cuneo

Numico G; Ferrua R; Fea E; Giamello J; Colantonio I; Occelli M; Vandone AM; Vanella P; Aimar G; Pisano C; Parlagreco E; Persano I; Milanesio M; Ippoliti R;

2021
ASL Asti
AO Cuneo
ASL Città di Torino
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Berruti A; Tucci M; Gennari A; Baier S; Bellissimo AR; Ciccone G; Montagnani F; Comandone A; Chiappino I; Dal Canton O; Masini C; Sacco C; Zamparini M; Sirotova Z; Fea E; Valcamonico F; Vanella P; Ortega C; Buttigliero C; Prati V; Bianchi S; Mosca A; Dalla Volta A; Amoroso D;

First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. in World journal of clinical oncology / World J Clin Oncol. 2021 Nov 24;12(11):1037-1046. doi: 10.5306/wjco.v12.i11.1037.
2021
AO Cuneo

Buti S; Bersanelli M; Massari F; De Giorgi U; Caffo O; Aurilio G; Basso U; Carteni G; Caserta C; Galli L; Boccardo F; Procopio G; Facchini G; Fornarini G; Berruti A; Fea E; Naglieri E; Petrelli F; Iacovelli R; Porta C; Mosca A; Buti S; Bersanelli M; Massari F; De Giorgi U; Caffo O; Aurilio G; Basso U; Carteni G; et alii...

Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2020 Nov;139:81-89. doi: 10.1016/j.ejca.2020.08.009. Epub 2020 Sep 23.
2020
AO Cuneo

Aprile G; Grande R; Boccaccino A; Tamburini E; Fea E; Bordonaro R; Marmorino F; Buonadonna A; Pietrantonio F; Zaniboni A; Antoniotti C; Caponnetto S; Tomasello G; Cupini S; Santini D; Bergamo F; Lonardi S; Zucchelli G; Moretto R; Rossini D; Falcone A; Cremolini C;

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib. in World journal of gastrointestinal oncology / World J Gastrointest Oncol. 2020 Mar 15;12(3):301-310. doi: 10.4251/wjgo.v12.i3.301.
2020
AO Cuneo

Ricci V; Granetto C; Falletta A; Paccagnella M; Abbona A; Fea E; Fabozzi T; Lo Nigro C; Merlano MC; Ricci V; Granetto C; Falletta A; Paccagnella M; Abbona A; Fea E; Fabozzi T; Lo Nigro C; Merlano MC;

Heterogeneity of colon cancer: from bench to bedside. in ESMO open / ESMO Open. 2017 Aug 22;2(3):e000218. doi: 10.1136/esmoopen-2017-000218. eCollection 2017.
2017
AO Cuneo

Merlano MC; Granetto C; Fea E; Ricci V; Garrone O;

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Apr;26(4):724-730. doi: 10.1093/annonc/mdv012. Epub 2015 Jan 18.
2015
AO Cuneo

Masi G; Salvatore L; Boni L; Loupakis F; Cremolini C; Fornaro L; Schirripa M; Cupini S; Barbara C; Safina V; Granetto C; Fea E; Antonuzzo L; Boni C; Allegrini G; Chiara S; Amoroso D; Bonetti A; Falcone A;